This family has a history of being implicated in resistance against multiple therapies in different cancers15–17; for example, EGFR targeting therapy in bladder cancer18 and lung cancer19, sorafenib and imatinib resistance in renal cancer20, oxaliplatin21 and 5-FU22 resistance in colon cancer, paclitaxel and carboplatin resistance in ovarian cancer23 and nintedanib24 and paclitaxel25 resistance in lung cancer. Here, EGFR is linked to malignant colon neoplasm.